Advanced Gastric Adenocarcinoma Clinical Trial
Official title:
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Treatment Naive Advanced Gastric Cancer: A Phase II Study.
This study is a single center, phase II study, to evaluate the effectiveness and safety of PD-1 Antibody(SHR-1210) Plus apatinib Combined With POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the first-line treatment for patients with advanced/metastatic gastric cancer.
This is a exploratory, single-arm, open-label trial. The investigator's primary purpose is to
compare that ORR of patients with camrelizumab plus apatinib and POF for advanced/metastatic
gastric cancer.
In treatment period, patients will be administrated camrelizumab plus apatinib and POF, every
28 days for 1 cycle, until disease progression, toxicity intolerance, withdrawal of informed
consent, patients judged must be terminated study termination.
The imaging evaluation was performed according to the RECIST 1.1 criteria every 8 weeks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04977193 -
A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma
|
Early Phase 1 | |
| Recruiting |
NCT04993378 -
Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy
|
||
| Recruiting |
NCT05583383 -
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
|
N/A | |
| Completed |
NCT06238752 -
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
|
Phase 2 | |
| Recruiting |
NCT04209686 -
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT02240524 -
Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer
|
Phase 3 | |
| Completed |
NCT02447380 -
Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT06203600 -
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05677490 -
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
|
Phase 3 | |
| Completed |
NCT02448329 -
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
|
Phase 2 | |
| Completed |
NCT02615730 -
PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05041153 -
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
|
Early Phase 1 | |
| Terminated |
NCT02449655 -
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
|
Phase 2 | |
| Completed |
NCT02449551 -
Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment
|
Phase 2 | |
| Completed |
NCT02599324 -
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06028737 -
Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04675866 -
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
|
N/A | |
| Completed |
NCT02447406 -
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03159819 -
Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
|
N/A |